IP Library › Granted Patent US 10,434,063
Granted Patent B2
US 10,434,063 · App. 15/928,057 · Granted Oct 8, 2019

Implant compositions for the unidirectional delivery of therapeutic compounds to the brain

Inventors: Michael J. McGinity (San Antonio, TX); Feng Zhang (Pflugerville, TX); John R. Floyd (San Antonio, TX); James W. McGinity (Austin, TX)
Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
A61K9/0085A61K9/0024A61K31/155A61K31/198A61K31/282A61K31/337A61K31/40A61K31/436A61K31/4745A61K31/495A61K31/519A61K31/538A61K31/573A61K31/661A61K31/704A61K33/24A61K39/3955A61K47/10A61K47/12A61K47/14A61K47/36A61L27/54A61L2430/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,434,063
App. No.
15/928,057
Granted
Oct 8, 2019
Kind
B2
Abstract

The present invention provides, in some aspects, bilayered and trilayered pharmaceutical implant compositions for the unidirectional delivery of anti-cancer compounds to the brain over a period of time (e.g., several weeks, 1, 2, 3, 4, 5, 6, 7 days, or 1, 2, 3, weeks, or any range derivable therein) following the removal of glioblastoma multiforme or other malignant tumors in the brain.

Claims (18)

1. A method of treating a brain cancer in a mammalian subject, comprising administering into a resection cavity in the brain of the subject an implant comprising at least two layers, a drug-containing layer having a drug elution surface to be positioned proximal to the tissue, and, a further layer or layers comprising a lipophilic backing layer and/or a hydrophobic coating, said further layer or layers being positioned distal to the drug elution surface, wherein:

a) the drug-containing layer comprises one or more drugs, a hydrophilic polymer or pore forming agent, and glyceryl behenate;

b) the lipophilic backing layer comprises glyceryl behenate; and

c) the hydrophobic coating comprises glyceryl behenate and coats surfaces of the implant that are not to be positioned proximal to the tissue; and

further, when each of layers a), b) and c) are present, the lipophilic backing layer is positioned between the drug-containing layer and the hydrophobic coating; and

wherein the drug elution surface is positioned proximal to the resection cavity, and, the further layer or layers comprising the lipophilic backing layer and/or the hydrophobic coating are positioned distal and/or lateral to the drug elution surface.

2. The method of claim 1 , wherein the subject is a mammal.

3. The method of claim 2 , wherein the mammal is a human.

4. The method of claim 1 , further comprising removing part or all of a tumor from the subject via the resection cavity.

5. The method of claim 4 , wherein the tumor is cancerous.

6. The method of claim 5 , wherein the tumor is a glioblastoma or glioblastoma multiforme.

7. The method of claim 5 , wherein the tumor is a high grade intrinsic brain tumor.

8. The method of claim 4 , wherein the cancer is a metastatic cancer.

9. The method of claim 1 , wherein the surface of the resection cavity or at least of the part the resection cavity is filled with a surgical glue or a fibrin glue.

10. The method of claim 9 , wherein the resection cavity is filled with a surgical glue.

11. The method of claim 9 , wherein the surgical glue is a fibrin glue.

12. The method of claim 1 , wherein part of the implant is covered with a biocompatible, biodegradable surgical fabric.

13. The method of claim 1 , wherein the brain cancer is glioblastoma or glioblastoma multiforme.

Continuity (5)
Division 15221827 · Jul 28, 2016
Provisional Application 62329973 · Apr 29, 2016
Provisional Application 62198040 · Jul 28, 2015
Provisional Application 62197739 · Jul 28, 2015
Related Publication 20180311157A1 · Nov 1, 2018
Cited By (2)
US 12,472,148 US 12,502,360